Tumor Neoantigens: When Too Much of a Good Thing Is Bad

Cancer Cell. 2019 Nov 11;36(5):466-467. doi: 10.1016/j.ccell.2019.10.009.

Abstract

Immunotherapy has been the most effective in tumors with high mutational burden. However, a recent study in Cell by Wolf et al. demonstrates that high intratumor heterogeneity (ITH) for cancer neoantigens paradoxically attenuates anti-tumor immune responses, suggesting a need to quantify ITH to improve patient selection for checkpoint blockade therapy.

Publication types

  • Comment

MeSH terms

  • Antigens, Neoplasm
  • Humans
  • Immunotherapy
  • Melanoma*
  • Mutation
  • Programmed Cell Death 1 Receptor / genetics

Substances

  • Antigens, Neoplasm
  • Programmed Cell Death 1 Receptor